<DOC>
	<DOCNO>NCT02009579</DOCNO>
	<brief_summary>Indication : Treatment subject advance ( FIGO stage IVB ) recurrent cervical cancer , prior radiochemotherapy neo-adjuvant chemotherapy allow . Study design : This phase II randomize , double blind placebo control trial evaluate efficacy Nintedanib/placebo combination standard 6 cycle 3 weekly carboplatin paclitaxel follow Nintedanib/placebo maintenance treatment patient advance recurrent cervical cancer . A total 120 patient randomized experimental control arm 1:1 ratio . Randomization stratify 1previous therapy ( chemo-radiotherapy neoadjuvant chemotherapy : , &gt; 6 month since last platin course ) 2disease status ( Stage IVB primary versus recurrent disease ) . Experimental arm : Subjects receive 6 cycle 3-weekly carboplatin ( AUC 5 ) + paclitaxel ( 175 mg/m2 ) Nintedanib 200 mg BID follow Nintedanib maintenance progression total maximum duration 120 week . Control arm : Subjects receive 6 cycle 3-weekly carboplatin ( AUC 5 ) + paclitaxel ( 175 mg/m2 ) placebo 200 mg BID follow placebo maintenance progression total maximum duration 120 week . Subjects without evidence disease progression completion discontinuation study treatment follow radiographic disease progression , withdrawal consent death .</brief_summary>
	<brief_title>ENGOT-cx1/BGOG-cx1 : 3 Weekly Carboplatin/Paclitaxel With Without Nintedanib Cervix Cancer</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Female subject 18 year age Histologically cytologically confirm advanced ( [ FIGO ] stage IVB ) , recurrent/persistent squamous cell carcinoma , adenosquamous carcinoma , adenocarcinoma cervix eligible . No prior chemotherapy recurrent cervical cancer . Prior concomitant cisplatinum chemotherapy radiotherapy allow ( except recurrence within 6 month end platinum contain chemotherapy ) . Cases primarily treat neoadjuvant chemotherapy radical local surgery eligible time first recurrence . ( except recurrence within 6 month end platinum contain chemotherapy ) . Cases primarily treat neoadjuvant chemotherapy radical local surgery follow adjuvant radiochemotherapy eligible time first recurrence ( except recurrence within 6 month end platinum contain chemotherapy ) . Cases primarily treat neoadjuvant chemotherapy radical local surgery follow adjuvant radiotherapy eligible time first recurrence ( except recurrence within 6 month end platinum contain chemotherapy ) . Life expectancy least 3 month . ECOG Performance status score 0 1 At least one measurable lesion accord RECIST 1.1 criterion Signed date write informed consent prior admission study accordance ICHGCP guideline local legislation Prior chemotherapy except platinbased concomitant chemotherapy radiotherapy Prior chemotherapy advance ( FIGO stage IVB ) recurrent disease except mention point 3.1.3 . Prior treatment nintedanib VEGFR inhibitor . Known hypersensitivity trial drug excipients . Brain leptomeningeal metastasis . Centrally locate tumor radiographic evidence ( CT MRI ) local invasion major blood vessel . Tumor infiltrate mucosa bowel bladder , know fistula tumor gastrointestinal urinary tract . Treatment investigational drug treatment another clinical trial within past 4 week start therapy concomitantly trial . Therapeutic anticoagulation antiplatelet therapy allow , unless patient stable anticoagulation Major injury within past 10 day prior start study treatment incomplete wound heal and/or plan surgery ontreatment study period . History clinically significant haemorrhagic thromboembolic event past 6 month . Known inherited predisposition bleed thrombosis . Significant cardiovascular disease ( i.e . uncontrolled hypertension , unstable angina within past 6 month , history infarction within past 6 month prior start study treatment , congestive heart failure &gt; NYHA II , serious cardiac arrhythmia , pericardial effusion ) . History cerebral vascular accident , transient ischemic attack subarachnoid haemorrhage within past 6 month . Abnormal renal , liver bone marrow function define : Proteinuria CTCAE grade 2 great Creatinin &gt; 2 ULN GFR &lt; 30 ml/min Hepatic function : total bilirubin outside normal limit ; ALT AST &gt; 1.5 ULN pt without liver metastasis . For Pts liver metastasis : total bilirubin outside normal limit , ALT AST &gt; 2.5 ULN Coagulation parameter : International normalise ratio ( INR ) &gt; 2 , prothrombin time ( PT ) partial thromboplastin time ( PTT ) &gt; 50 % deviation institutional ULN Absolute neutrophil count ( ANC ) &lt; 1500/µl , platelet &lt; 100000/µl , haemoglobin &lt; 9.0 g/dl Other malignancy within past 3 year malignancy recurrence past 3 year high risk recurrence first year . In exception rule , follow malignancy may include : nonmelanomatous skin cancer ( adequately treat ) , premalignant ( e.g . situ ) carcinoma , basocellular carcinoma . Active serious infection particular require systemic antibiotic antimicrobial therapy . Active chronic hepatitis C and/or B infection know HIV infection . Gastrointestinal disorder abnormality would interfere absorption study drug . Serious illness concomitant nononcological disease neurologic , psychiatric , infectious disease active ulcer ( gastrointestinal tract , skin ) laboratory abnormality may increase risk associate study participation study drug administration judgment investigator would make patient inappropriate entry study . Patients childbearing potential sexually active unwilling use medically acceptable method contraception ( e.g . implant , injectables , combine oral contraceptive , intrauterine device vasectomize partner sexual abstinence participate female ) trial least three month end active therapy . Pregnancy breast feeding , female patient must negative pregnancy test ( βHCG test urine serum ) prior commence study treatment , applicable . Psychological , familial , sociological geographical factor potentially hamper compliance study protocol followup schedule . Active alcohol drug abuse .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Uterine Cervical Cancer</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Nintedanib</keyword>
</DOC>